Burden of First Osteoporotic Hip Fracture in Spain: A Prospective, 12-Month, Observational Study
verfasst von:
Jose Ramón Caeiro, Agustí Bartra, Manuel Mesa-Ramos, Íñigo Etxebarría, Jorge Montejo, Pedro Carpintero, Francesc Sorio, Sonia Gatell, Andrea Farré, Laura Canals, on behalf of the PROA investigators
The purpose of this study was to estimate the burden of osteoporotic fractures beyond the hospitalization period covering up to the first year after the fracture. This was a prospective, 12-month, observational study including patients aged ≥65 years hospitalized due to a first low-trauma hip fracture, in six Spanish regions. Health resource utilization (HRU), quality of life (QoL) and autonomy were collected and total costs calculated. Four hundred and eighty seven patients (mean ± SD age 83 ± 7 years, 77 % women) were included. Twenty-two percent of patients reported a prior non-hip low-trauma fracture, 16 % were receiving osteoporotic treatment at baseline, and 3 % had densitometry performed (1.8 % T-score ≤−2.5). Sixteen percent of patients died (women 14 %; men 25 %; p = 0.0011) during the first year. Mean hospital stay was 11.8 ± 7.9 days and 95.1 % of patients underwent surgery. Other relevant HRUs were: outpatient visits in 78 % of patients (mean 9.2 ± 9.7); walking aids, 58.7 %; rehabilitation facilities, 35.5 % (28.7 ± 41.2 sessions); and formal and informal home care, 22.2 % (49.6 ± 72.2 days) and 53.4 % (77.1 ± 101.0 h), respectively. Mean direct cost was €9690 (95 % confidence interval: 9184–10,197) in women and €9019 (8079–9958) in men. Main cost drivers were: first hospitalization episode (women €7067 [73 %]; men €7196 [80 %]); outpatient visits (€1323 [14 %]; €997 [11 %]); and home care (€905 [9 %]; €767 [9 %]). QoL and autonomy showed a marked decrease during hospitalization, not entirely recovered at 12 months (p < 0.05 vs. baseline for EQ-5D, Harris hip score and modified Barthel index). In a Spanish setting, osteoporotic hip fractures incur a high societal and economic cost, mainly due to the first hospitalization HRU, but also due to subsequent outpatient visits and home care.
The online version of this article (doi:10.1007/s00223-016-0193-8) contains supplementary material, which is available to authorized users.
Introduction
Osteoporosis is characterized by compromised bone strength predisposing to an increased risk of fracture [1]. In the year 2000, there were approximately 9.0 million osteoporotic fractures with the greatest number occurring in Europe (34.8 %) [2]. Osteoporosis and resulting fractures have significant consequences on human health, QoL and societal burden [2]. Hip fractures place a high burden for patients and healthcare systems due to the advanced age of affected patients, the need for complex surgeries and the high impact on patients’ mobility [3]. However, this burden is systematically underestimated since usually only the admission period is considered. Hip fractures are also associated with a high mortality both during hospitalization [3] and following discharge [4].
In Spain, the annual incidence of hip fractures in patients aged ≥65 years has been estimated at 36,000 (90.5 % of all hip fractures) [3], and it is continuously increasing due to an ageing population (increase of 18 % between 1997 and 2008 [5]). There is limited evidence quantifying the burden of hip fractures at the Spanish national and regional levels, taking into account the differences between regional Health Systems, with only three retrospective chart review studies [6‐8] and one study extrapolating data from two clinical trials available [9]. Therefore, there is a need for an updated and reliable estimate of the cost of an osteoporotic hip fracture in Spain to help regions in their decision making.
Anzeige
The primary objective of this study was to estimate health resource utilization (HRU) and related costs associated with osteoporotic hip fractures over 12 months in patients of 65 years of age or older in Spain. The secondary objectives were: to describe patients’ characteristics, health-related quality of life (HRQoL), physical functioning and autonomy/dependency from others and the circumstances leading to the hip fracture.
Patients and Methods
The PROA (PRospective Observational study on burden of hip frActures in Spain) was a prospective, 12-month, observational study. Patients ≥65 years admitted to hospital due to a first osteoporotic hip fracture (defined as fracture due to a low impact or falling from a standing height or less or any mild or moderate trauma not resulting from a fall [10]) were included. The exclusion criteria were: hip fracture secondary to severe trauma (defined as a fall from a height higher than that of a stool, chair or first rung of a ladder, or severe trauma other than a fall), concurrent non-hip fracture, malignancy or primary bone disease, and participation in an interventional trial in the last 6 months. The protocol was approved by an independent ethics committee, and all patients gave written informed consent before enrolment. For patients who suffered from cognitive impairment, informed consent was given by a legal representative and patient-reported data were provided by the representative at each visit.
The study was conducted in six regions (Andalusia, Basque Country, Catalonia, Galicia, Madrid and Valencia) including small (<200 beds), medium (200–500 beds) and large hospitals (>500 beds). Data were collected at baseline (first admission to hospital), hospital discharge and 4 and 12 months post-fracture. At baseline, the following variables were collected: demographic data, fracture risk factors, comorbidities (Charlson comorbidity index [11, 12]) and circumstances of the fall/event leading to the hip fracture. Fracture-associated HRUs were collected at all visits: inpatient care (length of hospital stay, imaging, type of surgery and/or prosthesis, treatment of complications); re-hospitalizations; ambulatory care (number and type of outpatient visits; physician or nurse), home visits (occupational therapist, physician and nurse) and/or telephone support; rehabilitation (number of physiotherapy sessions); walking aids; visits to emergency departments; and formal (social workers, nursing home stay, rehabilitation facility stay) and/or informal home care (relatives or paid worker). HRQoL (EuroQoL-5 dimensions [EQ-5D] questionnaire [13, 14]) and patient autonomy (modified Barthel index [15] and Harris hip score [16]) were also collected at all visits (retrospectively at baseline, in reference to the status prior to the fracture). HRUs at the time of death were not collected.
Statistical Analysis
The Spanish Healthcare System perspective has been applied, except for the informal home care resources. Unitary costs were obtained from the eSalud database (http://www.oblikue.com/bddcostes) and adjusted to 2012 values. Mean annual costs and 95 % confidence intervals (CI) were calculated (using 1000 bootstrap samples). The cost of informal home care was estimated by applying the official national minimum wage in Spain. Data regarding home support (formal or informal) before the fracture were asked to the patient or proxy responder (e.g. caregiver or relative) at the beginning of the study. The cost associated with hip fracture was computed as the difference between that of care provided before and after the fracture, as utilized in previous studies [17].
Anzeige
Descriptive analyses were provided for each variable at all the study visits. Changes in continuous variables over time were analysed using paired T tests. Differences between subgroups of patients were tested using Student’s T tests, Mann–Whitney or Chi-squared tests, as applicable. Time to death was summarized using Kaplan–Meier methodology. Survival differences between men/women were evaluated using a univariate Cox regression model. Statistical analyses were performed with the SAS statistical software package (SAS Institute, Inc, Cary, NC).
Results
Baseline Characteristics and Circumstances of the Fall Leading to the Hip Fracture
A total of 487 patients (77 % women) were included in 28 Spanish hospitals between 31 March 2011 and 29 June 2012. Of them, 357 (73.3 %) were followed up during 12 months. Most premature discontinuations (77/130, 59.2 %) were due to death.
Table 1 shows the main characteristics of the study cohort. The mean (SD) age of patients with a first osteoporotic hip fracture was similar for both sexes: 83.2 (6.6) and 81.1 (7.0) for women and men, respectively. Around one-third of patients had at least one previous non-hip fracture, of which 59.7 % had been reported as low impact fractures. A total of 15.6 % of patients were receiving osteoporotic treatment at the time of the fracture occurrence, and only 3 % had undergone bone densitometry testing (1.8 % had BMD T-score ≤−2.5).
Table 1
Baseline characteristics and osteoporosis risk profile of patients with a first osteoporotic hip fracture in Spain
Women (N = 375)
Men (N = 112)
Total (N = 487)
Age, years, mean ± SD
83.2 (6.6)
83.1 (7.0)
83.2 (6.7)
≥75 years
339 (90.4)
100 (89.3)
439 (90.1)
Sex, woman
–
–
375 (77.0)
Type of centre
Small
67 (17.9)
26 (23.2)
93 (19.1)
Medium
101 (26.9)
37 (33.0)
138 (28.3)
Large
207 (55.2)
49 (43.8)
256 (52.6)
Alcohol intake
21 (5.6)
26 (23.2)
47 (9.6)
Active smoking
7 (1.9)
11 (9.8)
18 (3.7)
Body mass index (kg/m2)
<18.5
8 (2.1)
0 (0)
8 (1.6)
18.5–<25.0
159 (42.4)
51 (45.5)
210 (43.1)
25.0–<30.0
112 (29.9)
39 (34.8)
151 (31.0)
≥30.0
58 (15.5)
12 (10.7)
70 (14.4)
Missing
38 (10.1)
10 (8.9)
48 (9.9)
Diagnosis of osteoporosis established by densitometry (T-score ≤−2.5)
8 (2.1)
1 (0.9)
9 (1.8)
T-score not available
362 (96.5)
110 (98.2)
472 (96.9)
Secondary osteoporosisa
10 (2.7)
4 (3.6)
14 (2.9)
Prior non-hip fracture
144 (38.4)
37 (33.3)
181 (37.2)
Prior non-hip fracture by low impact trauma
88 (23.5)
20 (17.9)
108 (22.2)
Time since last fracture, months, median (Q1, Q3)b
42.1 (18.7, 109.5)
75.8 (28.2, 163.7)
43.0 (20.4, 123.4)
Location of previous fracturesc
Wrist
50 (13.3)
10 (8.9)
60 (12.3)
Shoulder
24 (6.4)
4 (3.6)
28 (5.7)
Spine
16 (4.3)
7 (6.3)
23 (4.7)
Upper arm
17 (4.5)
2 (1.8)
19 (3.9)
Other
67 (17.9)
16 (14.3)
87 (17.9)
Prior osteoporotic treatment
70 (18.7)
6 (5.4)
76 (15.6)
Other risk factors for fracture
Parental hip fracture
21 (5.6)
9 (8.0)
30 (6.2)
Use of glucocorticoids
22 (5.9)
5 (4.5)
27 (5.5)
Diagnosis of rheumatoid arthritis
13 (3.5)
1 (0.9)
14 (2.9)
Main comorbidities
Diabetes
75 (20.0)
24 (21.4)
99 (20.3)
Dementia
44 (20.5)
18 (16.1)
95 (19.5)
Cerebrovascular disease
54 (14.4)
28 (25.0)
82 (16.8)
Congestive heart failure
45 (12.0)
13 (11.6)
58 (11.9)
Peripheral vascular disease
48 (12.8)
8 (7.1)
56 (11.5)
Chronic pulmonary disease
22 (5.9)
26 (23.2)
48 (9.9)
Myocardial infarction
29 (7.7)
19 (17.0)
48 (9.9)
Any tumour
13 (3.5)
8 (7.1)
21 (4.3)
Moderate or severe renal disease
13 (3.5)
8 (7.1)
21 (4.3)
Charlson index, mean (SD)d
1.8 (1.1)
2.4 (1.7)
1.9 (1.3)
Hip fracture result of a fall
373 (99.5)
110 (98.2)
483 (99.2)
Living arrangements prior to the fall
Alone in own home
82 (21.9)
11 (9.8)
93 (19.1)
Partner/family member sharing own home
219 (58.4)
79 (70.5)
298 (61.2)
Nursing home
40 (10.7)
15 (13.4)
55 (11.3)
Relatives home
33 (8.8)
7 (6.3)
40 (8.2)
Patient alone at the time of a fall
172 (45.9)
38 (33.9)
210 (43.1)
Where fall happened
Inside
294 (78.4)
84 (75.0)
378 (77.6)
Outside
79 (21.1)
26 (23.2)
105 (21.6)
Missing
2 (0.5)
2 (1.8)
4 (0.8)
If fall happened outside, weather conditions
Dry
68 (18.1)
21 (18.8)
89 (18.3)
Wet
10 (2.7)
4 (3.6)
14 (2.9)
Icy
1 (0.3)
1 (0.9)
2 (0.4)
Season when the fall took place
Winter
59 (15.7)
19 (17.0)
78 (16.0)
Spring
74 (19.7)
28 (25.0)
102 (20.9)
Summer
103 (27.5)
28 (25.0)
131 (26.9)
Autumn
137 (36.6)
35 (31.3)
172 (35.3)
Missing
2 (0.5)
2 (1.7)
4 (0.8)
Patient receiving medications that increase the risk of falls
136 (36.3)
35 (31.3)
171 (35.1)
Data are number of patients (percentage) except when otherwise indicated; a defined as conditions such as type I diabetes, osteogenesis imperfecta, untreated long-standing hyperparathyroidism, hypogonadism or premature menopause, chronic malnutrition, or malabsorption and chronic liver disease; b calculated at enrolment in patients with a previous non-hip fracture; c subjects could have multiple previous fractures at different locations; subjects with more than one fracture in the same location were counted only once in that location; d valid N = 256/86/342 for women, men and overall, respectively; Q1 = 25th percentile; Q3 = 75th percentile; SD standard deviation
The majority of patients lived with a partner or family member sharing their own home (61.2 %), with 19.1 % living alone, 11.3 % living in a nursing home and 8.2 % living in a relative’s home. The circumstances of the fall leading to the hip fracture were similar between men and women. Most falls occurred inside, in the morning and in autumn or summer. Approximately one-third (35.1 %) of subjects were receiving medications that increase the risk of falls (Table 1).
During the follow-up, 18 (3.7 %) patients had at least one new fracture (total of 19 fractures, 95 % osteoporotic origin).
Health-Related Quality of Life and Patient Autonomy
The HRQoL results and changes in patient autonomy showed a statistically significant decrease during hospitalization and up to 12 months after (Table 2). Furthermore, patients living independent of caregivers or family members decreased after 12 months compared to baseline (36 vs. 77, respectively) (Online Resource 1).
Table 2
Changes in health-related quality of life and patient autonomy during the 12-month follow-up
Baseline (prior to the fracture)
Discharge
4 months
12 months
EQ-5D, health state index, mean (SD)a
0.57 (0.39)
0.04 (0.39)*
0.47 (0.41)*
0.53 (0.41)*
Valid N
454
446
303
318
Change from baseline, mean (95 % CI)
−0.54 (−0.58 to −0.50)
−0.11 (−0.16 to −0.06)
−0.06 (−0.11 to −0.01)
Harris hip score, mean (SD)b
74.9 (19.6)
46.6 (14.6)*
64.7 (17.9)*
69.1 (18.9)*
Valid N
353
341
223
244
Change from baseline, mean (95 % CI)
−28.3 (−30.4 to −28.3)
−9.9 (−12.6 to −7.2)
−7.1 (−9.7 to −4.5)
Modified Barthel index, mean (SD)c
77.5 (26.9)
40.4 (24.3)*
66.4 (31.4)*
70.4 (31.1)*
Valid N
441
433
287
306
Change from baseline, mean (95 % CI)
−37.3 (−39.5 to −35.1)
−12.2 (−14.9 to −9.5)
−9.8 (−12.5 to −7.1)
aThe health state index score ranges between −0.594 and 1.0. A higher score indicates a more preferred health status, b Harris hip score ranges between 0 and 100. A higher score indicates better function, c the modified Barthel index ranges between 0 and 100. A higher score indicates better function
* p < 0.05 versus baseline
Health Resource Utilization
HRU was high, both during the first hospitalization and at 12-month follow-up. The results were similar across genders, except for re-hospitalizations which were more frequent among women versus men (6.4 vs. 3.6 %).
The 95.1 % of patients underwent surgery, mainly intramedullary nail osteosynthesis in women and partial prosthesis in men. Mean length of hospital stay during first hospitalization was 11.8 ± 7.9 days (Tables 3, 4).
Table 3
Health resource utilization
Women (N = 375)
Men (N = 112)
Total (N = 487)
First hospitalization
Hospital stay, days, mean (SD)
11.8 (7.9)
11.9 (8.1)
11.8 (7.9)
Median (min–max)
10.0 (1–69)
10.0 (2–54)
10.0 (1–69)
Geriatric ward, %
0.5
1.7
0.8
Days, mean (SD)
5.0 (1.4)
12.0 (2.8)
8.5 (4.4)
Intensive care, %
26.7
22.3
25.7
Days, mean (SD)
1.0 (0.2)
1.5 (2.0)
1.1 (0.9)
Orthopaedic ward, %
99.2
98.2
99.0
Days, mean (SD)
11.4 (7.7)
11.4 (8.0)
11.4 (7.8)
Other wards, %
2.1
0.8
3.7
Days, mean (SD)
2.9 (5.3)
1.7 (1.6)
2.2 (3.6)
Surgical intervention, %
95.7
92.9
95.1
Intramedullary nail osteosynthesis
45.3
31.3
42.1
Sliding screw osteosynthesis
17.6
17.9
17.7
Partial prosthesis
28.5
36.6
30.4
Total prosthesis
4.8
8.0
5.5
Imaging
96.8
99.1
97.3
CT, %
5.9
6.2
6.0
Num. times used, mean (SD)
1.2 (0.5)
1.0 (0)
1.2 (0.5)
Ultrasound, %
4.3
4.5
4.3
Num. times used, mean (SD)
1.1 (0.3)
1.4 (0.9)
1.1 (0.5)
X-ray, %
96.8
99.1
97.3
Num. times used, mean (SD)
4.0 (1.8)
4.2 (1.7)
4.0 (1.8)
Other proceduresa, %
0.5
58.9
49.9
Num. times used, mean (SD)
5.8 (3.5)
6.4 (5.0)
5.9 (3.9)
Emergency room visit prior to hospitalization, %
86.9
84.8
86.4
12-month follow-up
Re-hospitalizations, %
6.4
3.6
5.7
Hospital stay, days, mean (SD)
16.2 (13.9)
5.8 (4.5)
14.7 (13.4)
Median (min–max)
12.5 (2–56)
4.5 (2–12)
10.5 (2–56)
Imaging, %
5.9
3.6
5.3
Surgical intervention, %
0.8
0
0.6
Intramedullary nail osteosynthesis
0.5
0
0.4
Partial prosthesis
0.3
0
0.2
Other proceduresa, %
4.3
3.6
4.1
Ambulatory care
Outpatient visits, %
81.3
67.0
78.0
Number of visits, mean (SD)
9.1 (9.5)
9.4 (10.9)
9.2 (9.7)
Median (min–max)
6.0 (1–75)
6 (1–58)
6 (1–75)
Nurse at health centre visits, %
31.7
31.2
31.6
Number of visits, mean (SD)
3.2 (4.9)
1.9 (1.4)
2.9 (4.4)
Nurse’s home visits, %
39.5
33.0
38.0
Number of visits, mean (SD)
5.8 (7.1)
7.1 (8.5)
6.0 (7.4)
Physician at health centre visits, %
38.7
38.4
38.6
Number of visits, mean (SD)
3.0 (2.4)
2.8 (2.3)
3.0 (2.4)
Specialist, %
61.9
57.1
60.8
Number of visits, mean (SD)
3.1 (2.5)
2.8 (3.0)
3.0 (2.6)
Physician’s home visits, %
29.1
15.2
25.9
Number of visits, mean (SD)
3.4 (3.8)
4.6 (4.3)
3.6 (3.9)
Rehabilitation facility, %
36.3
33.0
35.5
Number of sessions, mean (SD)
28.5 (43.2)
29.6 (33.5)
28.7 (41.2)
Median (min–max)
16 (1–320)
14 (1–128)
15 (1–320)
Health centre, %
14.7
11.6
14.0
Number of sessions, mean (SD)
27.4 (25.3)
36.8 (38.5)
29.2 (28.2)
Home, %
24.5
25.9
24.8
Number of sessions, mean (SD)
25.7 (41.1)
21.3 (23.9)
24.7 (37.6)
Imaging, %
4.0
1.8
3.5
Num. times used, mean (SD)
6.5 (4.7)
6.0 (5.7)
6.4 (4.6)
Other proceduresa, %
2.4
1.8
2.3
Num. times used, mean (SD)
2.0 (1.7)
2.5 (2.1)
2.1 (1.6)
Ambulance use, %
53.3
37.5
49.7
Num. times used, mean (SD)
5.0 (10.6)
4.0 (4.4)
4.8 (9.8)
Visits to emergency room, %
16.0
14.3
15.6
Num. times used, mean (SD)
1.9 (2.2)
1.4 (0.7)
1.8 (2.0)
Walking aids, %
60.3
53.6
58.7
Walker
49.9
44.6
48.7
Wheelchair
16.5
14.3
16.0
Home care
Formal, %
23.7
17.0
22.2
Days, mean (SD)
47.1 (66.7)
61.6 (95.1)
49.6 (72.2)
Median (min–max)
26.5 (1–411)
47.0 (1–618)
25.1 (1–411)
Care from social workers, %
4.5
5.4
4.7
Days, mean (SD)
6.6 (8.2)
5.8 (2.8)
6.4 (7.2)
Nursing home, %
8.8
4.5
7.8
Days, mean (SD)
56.7 (63.5)
110.0 (96.9)
63.7 (69.6)
Rehabilitation facility, %
15.5
10.7
14.4
Days, mean (SD)
38.1 (38.0)
48.7 (45.3)
39.9 (39.2)
Informal, %
56.5
42.9
53.4
Hours, mean (SD)
78.0 (103.7)
73.1 (89.3)
77.1 (101.0)
Median (min–max)
35 (1–672)
38 (2–336)
35 (1–672)
Cared by relatives, %
49.3
39.3
47.0
Hours, mean (SD)
64.7 (81.7)
61.8 (79.4)
64.1 (81.1)
Paid worker, %
24.5
16.1
22.6
Hours, mean (SD)
49.6 (69.9)
44.0 (67.3)
48.7 (69.2)
Mean (SD) number of each HRU calculated among those patients reporting 1 or more
aMainly blood tests; CT computed tomography, SD standard deviation
Table 4
Direct medical costs during the first year after a first osteoporotic hip fracture
Mean € (95 % CI)
Women (N = 375)
Men (N = 112)
Total direct cost
9690 (9184, 10,197)
9019 (8079, 9958)
First hospitalization
First hospitalization
7067 (6733, 7401)
7196 (6522, 7870)
Hospital stay
4796 (4469, 5122)
4856 (4240, 5472)
Geriatric ward
11 (0, 26)
88 (0, 211)
Intensive care
154 (127, 181)
184 (66, 301)
Orthopaedic ward
4631 (4311, 4950)
4584 (3964, 5205)
Surgical intervention
2064 (1997, 2131)
2128 (1969, 2288)
Intramedullary nail osteosynthesis
795 (706, 884)
545 (393, 697)
Sliding screw osteosynthesis
401 (312, 490)
401 (239, 562)
Partial prosthesis
691 (580, 803)
887 (667, 1106)
Total prosthesis
177 (97, 257)
296 (108, 484)
Imaging
89 (83, 94)
96 (87, 106)
Computed tomography
6 (3, 8)
5 (1, 9)
Ultrasound
4 (2, 5)
5 (0, 10)
X-ray
80 (76, 84)
87 (80, 94)
Emergency room visit prior to hosp.
118 (114, 123)
115 (106, 125)
12-month follow-up
Re-hospitalizationb
395 (173, 617)
59 (0, 120)
Ambulatory care
1323 (1119, 1528)
997 (753, 1241)
Outpatient visits
329 (291, 367)
281 (204, 359)
Nurse at health centre visits
16 (11, 21)
10 (6, 13)
Nurse’s home visits
73 (56, 91)
75 (40, 110)
Physician at health centre visits
56 (46, 66)
50 (33, 68)
Specialist
122 (106, 138)
104 (72, 135)
Physician’s home visits
62 (46, 78)
43 (16, 70)
Rehabilitation facility
284 (191, 376)
258 (142, 373)
Health centre
48 (32, 65)
52 (12, 91)
Home
235 (148, 323)
206 (100, 313)
Imaging
6 (2, 10)
3 (0, 8)
Ambulance use
486 (336, 635)
269 (157, 382)
Visits to emergency room
42 (26, 57)
29 (14, 44)
Walking aids
177 (148, 207)
157 (104, 210)
Walker
55 (49, 62)
49 (37, 60)
Wheelchair
122 (92, 152)
109 (55, 162)
Home care, mean use
905 (690, 1121)
767 (285, 1250)
Formal
603 (397, 810)
563 (116, 1009)
Care from social workers
18 (5, 31)
18 (3, 35)
Nursing home
258 (129, 387)
254 (−30, 538)
Rehabilitation facility
327 (213, 441)
290 (74, 506)
Informal
302 (236, 368)
205 (114, 296)
Cared by relatives
162 (128, 196)
123 (68, 178)
Paid worker
140 (93, 188)
81 (15, 148)
CI confidence interval, Hosp hospitalization
Anzeige
There was a large number of outpatient visits (median: 6.0, range: 1–75), use of rehabilitation facilities (median: 15 sessions, range: 1–320), walking aids (58.7 % of patients) and home care (22.2 % of patients with formal care [median of 25 days] and 53.4 % with informal care [median of 35 h]) (Table 3). Seventy-seven patients (15.8 %) required both formal and informal home care.
Direct Medical Costs
Mean total cost during the first year was €9690 (95 % CI: 9184–10,197) in women and €9019 (8079–9958) in men, with no significant differences between genders except for the cost of re-hospitalizations (Table 4).
The main cost determinant was first hospitalization (€7067 and €7196 in women and men, respectively), followed by ambulatory care and home care (Table 4).
Subgroup Analyses by Size of Centre
When HRU was analysed by size of centre, large centres showed longer hospital stays (mean of 13.8 days versus 10.2 and 9.0 in small and medium centres, respectively). However, after discharge, patients treated at small centres had more outpatient visits (mean of 10.0 [in all patients] versus 6.3 and 6.5 in medium and large centres), rehabilitation sessions (mean of 17.1 vs. 10.7 and 7.4) and formal home care (mean of 16.6 days vs. 10.5 and 9.3), but less informal care (mean of 29.1 h vs. 48.6 and 41.5 in medium and large centres).
Anzeige
Mortality
During the 12-month follow-up, 15.8 % of patients died, 53 % of them within the first 3 months (Fig. 1). Mortality was significantly higher in men than in women (24.1 vs. 13.4 %, respectively, p = 0.0011).
Fig. 1
Mortality in the overall group and by gender in the first year after a first osteoporotic hip fracture
×
Discussion
The PROA constitutes the first large, multicentre, prospective study specifically designed to provide estimates on the cost of osteoporotic hip fractures in Spain. Overall, the socio-demographic characteristics of our cohort were comparable to those from similar studies conducted in Belgium [18], Sweden [19] or the UK [20]. Nevertheless, there were some notable differences between this and other national studies. The mean age of this cohort was similar for both sexes and higher than that reported previously, most likely due to the comparatively higher proportion of patients aged 75 years old or above [3, 21, 22]. Furthermore, while the proportion of patients sharing their own home/living alone was similar to that of the Spanish population, the proportion of patients living in a nursing home was greater in this cohort compared to national averages [23]. Lastly, the prevalence of prior vertebral fractures was extremely low (4.7 %) compared to the estimated 20 % in the Spanish population of similar age, most likely due to the fact that in this study only fractures that were documented in the patient’s medical file were collected as opposed to the acquisition of X-rays of the thoracic and lumbar spine using the Genant method [24, 25]. That being said, the similar prevalence of vertebral fractures previously registered in the patient’s file (1.2–4.3 %) reflects the underdiagnosis of these fractures in the daily practice [24].
Of note, almost all first osteoporotic hip fractures occurred in individuals at high risk of fracture, although only a low percentage were previously diagnosed and treated for osteoporosis. The treatment gap (patients eligible for treatment not receiving any drug) for osteoporosis in 2010 was estimated between 57 % (women) and 59 % (men) in the European Union [1]. In Spain, this gap was 25 and 20 %, but in our cohort it could be >30 %, according to the high prevalence of prior osteoporotic fractures and an important underuse of osteoporotic treatments in the recent years [26].
Similarly to previous studies [18, 19, 27], HRU during hospitalization was high, mainly related to a long hospital stay and to the need for surgery. The mean hospital stay (12 days) was similar than that reported in local studies [7] and in a previous analysis of Minimum Basic Data Set between 1997 and 2008 (13 days) [28], but much lower than the 23-day length reported in 1989 [8]. Health resource utilization in the first year following hospital discharge was similar to the observed in Sweden or Belgium [18, 19, 27]. The proportion of patients with re-hospitalization related to the hip fracture was very low in comparison with previous studies that collected all type of hospitalizations (17–30 %) [29, 30].
Anzeige
The cost obtained for the first hospitalization (~€7000) was consistent with the disease-related groups applicable to hip fracture in Spain (210, 211, 236, 558 and 818, cost: €2684-€14,878) [28]. This cost increased by 70 % between 1997 and 2008 in Spain (€4909 to €8365) [8, 28], probably related to the increase in mean age (2 years) and comorbidities of the patients, and the increase in the number of surgical interventions (86 % in 1997) [28].
The total cost in the first year after the first fracture (~€9000) is higher than that reported in Spain after a non-fatal stroke (€4638) but lower than after a myocardial infarction (€19,277) [31]. Our study suggests that, if only the first hospitalization is considered, one-fourth of the total annual cost of a hip fracture might be underestimated.
Compared to other European countries, the cost seems to be approximately a 25 % lower (€13,470 in Belgium; €14,221 in Sweden). In a UK cohort, the cost was slightly lower (€7536) [20], but in that study the costs associated with rehabilitation services and home care were not taken into account.
Mortality was high, especially in males (24.1 %). In both genders, mortality rates were almost three times higher compared to the annual mortality rate of Spanish general population of a similar age (7.4 and 4.5 %, respectively, in males and females of 80–84 years old) [32].
Prior to the fracture, the HRQoL was similar to that reported in Spanish population aged ≥85 [33], but it showed a marked worsening during the hospital stay and was not entirely resolved after 12 months, highlighting the long-term burden of the hip fracture.
Our study has some limitations. The similarity in age between sexes combined with the high proportion of patients aged 75 years old or above may limit the generalizability of these results to all patients with osteoporotic hip fractures in Spain aged ≥65 years old. The total cost may have been underestimated due to the inability of the study to collect the HRU at the time of death, inherent to the nature of observational design. Patient-reported HRU after hospital discharge, such as visits to the general practitioner, emergency room visits or re-hospitalizations, may have been underestimated due to the inability of the patient to recall information, leading to potential misclassification.
Strengths of our study include the large sample size and the geographically distributed recruitment, which ensures that it represents the regional diversity of Spain. Also, the prospective follow-up allowed a more comprehensive data collection on both the economic and humanistic burden of the condition not routinely included in patients’ medical records.
In conclusion, in a Spanish setting, osteoporotic hip fractures incur a high societal and economic cost, mainly due to the high HRU during the first hospitalization, but also due to subsequent outpatient visits and home care. Hip fractures were also associated with a high mortality of approximately one in six patients during the first year. The high prevalence of known risk factors and the low number of patients receiving prophylactic treatment highlight the undertreatment of this population, typically women older than 75 years with prior fractures, several comorbidities such as diabetes or dementia, and receiving medications that increase the risk of falls. By comparison, men in this study cohort not only received less osteoporosis follow-up prior to the hip fracture, but also exhibited a greater frequency of risk factors such as smoking and excessive alcohol consumption. Together, these results reflect the need for improving the diagnostic and therapeutic management of osteoporosis in Spain.
Acknowledgments
Writing assistance was supported by Amgen and provided by Neus Valveny, PhD, from TFS Develop. The authors wish to thank Jorge Arellano (MSc, Amgen Inc) for his contribution to the study design, and all the Investigators of the PROA Study (in alphabetical order by hospital name): Complejo Hospitalario Ourense: Dr. Antonio Fernández-Cebrián; Complejo Hospitalario Pontevedra—Hospital Montecelo: Dr. Eduardo Vaquero-Cervino; Complejo Hospitalario Santiago—Hospital Médico Quirúrgico de Conxo: Dr. José Ramón Caeiro; Fundación Jiménez Díaz: Dr. Emilio Calvo; Hospital Alto Deba: Dr. Íñigo Etxebarría-Foronda; Hospital Regional Universitario Carlos Haya: Dr. Manuel Bravo-Bardají; Hospital Comarcal Sant Bernabe de Berga, Dr. Pere Mir-Batlle; Hospital da Costa: Dr. Luís-Ángel Montero-Furelos; Hospital Universitario Donostia: Dr. Gaspar de la Herran-Núñez; Hospital Universitario de la Ribera: Dr. Francisco José Tarazona-Santabalbina; Hospital Txagorritxu: Dr. Rubén Goñi-Robledo, Dra. Naiara Gorostiaga-Perez; Hospital de Vinarós: Dr. Miguel-Angel Valero-Queralt; Hospital El Escorial: Dr. Guillermo Sánchez-Inchausti; Hospital General Universitario de Alicante: Dra. Isabel Serralta-Davia; Hospital General de Vic: Dr. Joaquín Rodríguez-Miralles; Hospital Universitari Germans Trias i Pujol: Dr. Xavier Granero-Xiberta; Hospital Universitario Infanta Leonor: Dra. Fátima Brañas-Baztán; Hospital Lluís Alcanyís: Dr. Vicente Climent-Peris; Hospital Municipal de Badalona: Dra. Núria Galofré-Álvaro, Dra. Ana Serrado-Iglesias, Dra. Josefa Torres-Martínez; Hospital Universitari Mútua de Terrassa: Dr. Agustí Bartra-Ylla; Hospital Universitario Ramón y Cajal: Dra. Susana Alonso-Güemes; Hospital Universitario Reina Sofía: Dr. Pedro Carpintero-Benítez; Hospital San Agustín de Linares: Dr. Alberto Delgado-Martínez; Hospital Universitario de Getafe: Dr. Leocadio Rodríguez-Mañas, Dra. Cristina Alonso-Bouzón, Dra. Olga Laosa-Zafra; Hospital Universitario Fundación Alcorcón: Dr. Jorge Montejo-Sancho; Hospital Universitari Vall d’Hebrón: Dr. Vicente Molero-García; Hospital Valle de los Pedroches: Dr. Manuel Mesa-Ramos; Hospital Virgen de la Macarena: Dr. Luís-Javier Roca-Ruíz.
Funding
This study was sponsored by Amgen, S.A.
Authors’ Contribution
Jose Ramón Caeiro, Manuel Mesa-Ramos, Francesc Sorio, Sonia Gatell and Laura Canals designed the study. Jose Ramón Caeiro, Agustí Bartra, Manuel Mesa-Ramos, Íñigo Etxebarría, Jorge Montejo, Pedro Carpintero and Andrea Farré contributed to the experimental work. All authors were responsible for analysis of the data. All authors revised the paper critically for intellectual content and approved the final version. All authors agree to be accountable for the work and to ensure that any questions relating to the accuracy and integrity of the paper are investigated and properly resolved.
Compliance with Ethical Standards
Conflict of interest
F Sorio, S Gatell, A Farre and L Canals are employees of Amgen. JR Caeiro has participated as principal investigator and/or collaborator in clinical trials sponsored by Lilly and Amgen and has been speaker at scientific events of Lilly, Merck, Pfizer and Servier. M. Mesa has been principal investigator in a clinical trial sponsored by Nycomed and speaker at scientific events of Procter & Gamble, Lilly and MSD. P Carpintero has participated as principal investigator in clinical trials sponsored by Amgen, MSD, Lilly and Nycomed, has been speaker at scientific events of Amgen, MSD, Lilly and Nycomed and has been advisor of MSD, Lilly y Bayer. A Bartra, I Etxebarría and J Montejo declare that they have no conflict of interest.
Human and Animal Rights
All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards.
Informed Consent
Informed consent was obtained from all individual participants included in the study.
Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.
Burden of First Osteoporotic Hip Fracture in Spain: A Prospective, 12-Month, Observational Study
verfasst von
Jose Ramón Caeiro Agustí Bartra Manuel Mesa-Ramos Íñigo Etxebarría Jorge Montejo Pedro Carpintero Francesc Sorio Sonia Gatell Andrea Farré Laura Canals on behalf of the PROA investigators
Ob bei einer Notfalloperation nach Schenkelhalsfraktur eine Hemiarthroplastik oder eine totale Endoprothese (TEP) eingebaut wird, sollte nicht allein vom Alter der Patientinnen und Patienten abhängen. Auch über 90-Jährige können von der TEP profitieren.
Wenn unter einer medikamentösen Hochdrucktherapie der diastolische Blutdruck in den Keller geht, steigt das Risiko für schwere kardiovaskuläre Ereignisse: Darauf deutet eine Sekundäranalyse der SPRINT-Studie hin.
Insektenstiche sind bei Erwachsenen die häufigsten Auslöser einer Anaphylaxie. Einen wirksamen Schutz vor schweren anaphylaktischen Reaktionen bietet die allergenspezifische Immuntherapie. Jedoch kommt sie noch viel zu selten zum Einsatz.
Beginnen ältere Männer im Pflegeheim eine Antihypertensiva-Therapie, dann ist die Frakturrate in den folgenden 30 Tagen mehr als verdoppelt. Besonders häufig stürzen Demenzkranke und Männer, die erstmals Blutdrucksenker nehmen. Dafür spricht eine Analyse unter US-Veteranen.
Update Innere Medizin
Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.
